Details for Patent: 9,101,621

Title:	Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
Abstract:	Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Filing Date:	Apr 17, 2014
Application Number:	14/255,211
Claims:	1. A method of treating multiple myeloma, which comprises administering to a patient having multiple myeloma about 1 to about 50 mg per day of a compound having the formula: ##STR00009## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein the patient has previously received stem cell transplantation. 2. The method of claim 1, wherein the multiple myeloma is relapsed, refractory, or relapsed and refractory multiple myeloma. 3. The method of claim 1, wherein the compound is administered for 21 consecutive days followed by seven consecutive days of rest in a 28 day cycle. 4. The method of claim 1, wherein the compound is administered every day. 5. The method of claim 1, wherein the compound is administered orally. 6. The method of claim 1, wherein the compound is administered in the form of a capsule or tablet. 7. The method of claim 1, wherein the compound is administered in a capsule of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg or 25 mg. 8. The method of claim 6, wherein the capsule comprises the compound, lactose anhydrous, microcrystalline cellulose, croscarmellose sodium and magnesium stearate. 9. The method of claim 1, wherein the compound is administered in an amount of about 25 mg per day. 10. The method of claim 1, wherein the compound is administered in an amount of about 15 mg per day. 11. The method of claim 1, wherein the compound is administered in an amount of about 10 mg per day. 12. The method of claim 1, wherein the compound is administered in an amount of about 5 mg per day. 13. The method of claim 3, wherein the compound is administered in an amount of about 25 mg per day. 14. The method of claim 4, wherein the compound is administered in an amount of about 5 mg, 10 mg or 15 mg per day. 15. The method of claim 1, wherein the stem cell transplantation is autologous stem cell transplantation. 16. The method of claim 1, wherein the stem cell transplantation is hematopoietic stem cell transplantation. 17. The method of claim 1, wherein the stem cell transplantation is peripheral blood stem cell transplantation. 18. The method of claim 1, wherein the compound is administered in an amount of about 2.5 mg per day. 19. The method of claim 3, wherein the compound is administered in an amount of about 10 mg per day. 20. The method of claim 1, wherein the compound is administered in an amount of about 20 mg per day. 21. The method of claim 1, wherein the compound is administered in a capsule containing from about 1 to about 50 mg of the compound.